HOME   Cart(1)   Quotation   About-Us Tax PDFs Standard-List
Powered by Google-Search & Google-Books www.ChineseStandard.net Database: 189760 (3 Dec 2022)

YY/T 0618-2017 (YYT 0618-2017)

YY/T 0618-2017_English: PDF (YYT0618-2017)
Standard IDContents [version]USDSTEP2[PDF] delivered inStandard Title (Description)Related StandardStatusPDF
YY/T 0618-2017English500 Add to Cart 0--3 minutes. Auto-delivered. Test methods for bacterial endotoxins of medical devices—Routine monitoring and alternatives to batch testing YY/T 0618-2017 Valid YY/T 0618-2017

BASIC DATA
Standard ID YY/T 0618-2017 (YY/T0618-2017)
Description (Translated English) Test methods for bacterial endotoxins of medical devices--Routine monitoring and alternatives to batch testing
Sector / Industry Medical Device & Pharmaceutical Industry Standard (Recommended)
Classification of Chinese Standard C30
Classification of International Standard 11.040.01
Word Count Estimation 34,390
Date of Issue 2017-02-28
Date of Implementation 2018-01-01
Older Standard (superseded by this standard) YY/T 0618-2007
Drafting Organization Shandong Province Medical Device Product Quality Inspection Center, the State Food and Drug Administration Tianjin Medical Device Quality Supervision and Inspection Center, Shanghai Songli Biological Technology Co., Ltd.
Administrative Organization National Medical Device Biology Evaluation Standardization Technical Committee (SAC/TC 248)
Proposing organization China Food and Drug Administration
Issuing agency(ies) State Food and Drug Administration

YY/T 0618-2017
YY
PHARMACEUTICAL INDUSTRY STANDARD
OF THE PEOPLE’S REPUBLIC OF CHINA
ICS 11.040.01
C30
Replacing YY/T 0618-2007
Test methods for bacterial endotoxins of medical devices -
Routine monitoring and alternatives to batch testing
ISSUED ON: FEBRUARY 28, 2017
IMPLEMENTED ON: JANUARY 01, 2018
Issued by: China Food and Drug Administration
Table of Contents
Foreword ... 3 
Introduction ... 4 
1 Scope ... 6 
2 Normative references ... 6 
3 Terms and definitions ... 6 
4 Principles of quality management system ... 11 
5 Non-pyrogenic label ... 13 
6 Selection of product unit ... 14 
7 Choice of technique ... 15 
8 Methodological validation ... 15 
9 Use of technique ... 20 
10 Alternatives to batch testing ... 24 
Appendix A (Informative) Background information on bacterial endotoxin testing .. 28 
Appendix B (Informative) Guidelines for test methods, routine monitoring, alternatives
to batch testing ... 32 
Appendix C (Informative) Out-of-specification (OOS) and failure investigation guide
... 50 
References ... 53 
Test methods for bacterial endotoxins of medical devices -
Routine monitoring and alternatives to batch testing
1 Scope
This standard specifies basic guidelines for test methods for bacterial endotoxins, which
are applicable to the determination of medical devices, components or raw materials.
Note: Although the scope of this standard is limited to medical devices, the requirements
specified in this standard and the guidelines given may also apply to other medical products.
This standard does not apply to the evaluation of pyrogens, other than bacterial
endotoxin.
2 Normative references
The following documents are essential to the application of this document. For the dated
documents, only the versions with the dates indicated are applicable to this document;
for the undated documents, only the latest version (including all the amendments) is
applicable to this standard.
Pharmacopoeia of the People's Republic of China 2015 Edition
3 Terms and definitions
The following terms and definitions apply to this document.
3.1
Bacterial endotoxin test; BET
Tests for the determination of active bacterial endotoxins, by mixing a liquid test
sample with Limulus amebocyte lysate, wherein the results of proportional
responses are measured by visual inspection, turbidity, chromogenic or other
validated test methods.
3.2
Batch
A specified quantity of raw material, intermediate or finished product, which is
The abnormal phenomenon of bacterial endotoxin test, which is caused by non-
endotoxin-related factors (usually caused by the characteristics of the test sample),
making the test response higher than the actual total amount of endotoxin present.
3.10
Gel-clot technique
The BET method for quantification or detection of endotoxin, which is based on the
principle that the resulting gel-clot reaction is a proportional reaction -- between the
Limulus amebocyte lysate and the endotoxin.
3.11
Geometric mean endpoint
The mean value, which is obtained from repeated serial dilutions, as converted to a
base 10 endpoint logarithm value; it is used for determining the central tendency or
mean value, from a test solution.
3.12
Inhibition
The abnormal phenomenon of bacterial endotoxin test, which is caused by non-
endotoxin-related factors (usually caused by the characteristics of the test sample),
so that the test response is lower than the actual total amount of endotoxin present.
3.13
Inhibition/enhancement test
A test, which is used to determine whether a specific bacterial endotoxin test sample
contains factors that reduce the accuracy of the test. That is, whether it inhibits or
enhances the test system.
3.14
Investigation test
Reanalysis of a sample extract or preparation, to verify the original test results.
3.15
LAL reactive material; LAL-RM
Any non-endotoxin component that activates the Limulus amebocyte lysate and
causes enhancement.
3.16
LAL reagent water; LRW
Purified water or other identified solvents, diluents and/or extractants, for use in
BET, which shall be non-reactive and non-interfering in the method used.
3.17
Lambda
The nominal lambda of the LAL gel reagent, expressed in EU/mL. OR, for
chromogenic and turbidimetric methods, refer to the nadir of the standard curve
(endotoxin concentration).
3.18
Limulus amebocyte lysate; LAL
Reagents which are extracted from the circulating blood amoeba of horseshoe crab
(Limulus polyphemus or Tachypleus tridentatus). It interacts with endotoxin to
produce gels, for bacterial endotoxin assays to determine bacterial endotoxin levels.
3.19
Lipopolysaccharide; LPS
Gram-negative bacterial cell wall components, which are typically composed of
lipid A, core polysaccharide, and O-side chains.
3.20
Maximum valid dilution; MVD
The maximum dilution of the sample, at which the specified test endotoxin limit can
be detected, in relation to the lambda of the BET.
3.21
Out of specification; OOS
Samples with valid BET test results exceeding the specification for product
endotoxin limits.
Note: The term OOS applies only to this document. It is different from other regulatory
guidance that deals with OOS results, such as the U.S. Food and Drug Administration (FDA)
"Studies of OOS Test Results for Drug Manufacturing".
3.29
Standard control series
Serial dilutions of RSE or CSE, which are used for validating endotoxin lambda.
3.30
Test endotoxin limit
The maximum endotoxin concentration is allowed in the extract. This determined
limit is used to calculate the maximum effective dilution factor, for sample leaching
(mix or one unit).
Note: This limit is determined by dividing the product endotoxin limit by the volume of
LRW used per unit of sample extract.
3.31
Turbidity technique
The BET method, for quantification or determination of endotoxin, which is based
on the principle that the measured color reaction is a proportional reaction -- between
the Limulus amebocyte lysate and the endotoxin.
3.32
Validation
Establish documented procedures for obtaining, recording, interpreting results, to
ensure that products conform to predetermined specifications.
4 Principles of quality management system
4.1 Document formation
4.1.1 The bacterial endotoxin test procedure shall be described in detail.
4.1.2 The documents and records which are required in this standard shall be reviewed
and approved by designated personnel (see 4.2.1). Meanwhile, it shall be under the
control of the specified quality management system requirements.
4.1.3 The retention of original data, calculated and derived data, final data records shall
be specified, in the quality management system requirements. Records shall include
information on those involved in sample preparation and testing.
The inspection technique steps and instructions used are approved. All relevant
equipment for use and operation shall be available.
4.1.4 Calculations and data transfer shall be properly controlled. If electronic data is
used, the software used shall be validated and a record of validation shall be kept.
4.2 Management responsibilities
4.2.1 Responsibilities and rights to complete and carry out the steps, which are
described in this document, shall be specified. Responsibility shall be given to those
who meet the requirements of the quality management system.
4.2.2 If an organization, which has a separate quality management system, undertakes
the requirements of this standard, the responsibilities and rights of each individual shall
be specified.
4.3 Product realization
The steps for procurement shall be detailed. These steps shall be consistent with the
quality management system requirements.
4.4 Personnel
4.4.1 The responsibilities of personnel, who are assigned to perform bacterial endotoxin
testing, shall be specified in the quality management system requirements.
4.4.2 The training shall be carried out in accordance with the documented procedures.
The records of the relevant identification, training, and experience of the technical
personnel shall be kept.
4.4.3 The analyst shall qualify the bacterial endotoxin test (see 8.3.2), before
undertaking it.
4.5 Equipment
4.5.1 All equipment which is required for the proper conduct of the specified tests, shall
be available. The planned maintenance and calibration shall be carried out, in
accordance with documented procedures. Maintenance and calibration records shall be
kept.
4.5.2 All equipment shall be operated in accordance with the document specifying the
guidelines.
4.6 Reagents and materials
4.6.1 The material preparation method, which is used in the bacterial endotoxin test,
shall be specified, including the corresponding identification test.
Note: The corresponding identification test includes the identification of the lambda of the
5.4 All components of the product claimed to be non-pyrogenic shall be included in the
test procedure. Any item of product within an exempt package shall be documented
(e.g., a handle or strap). Claims of "non-pyrogenic fluid circuits" shall be supported by
appropriate evaluation of the associated components and surfaces of the fluid circuits
used.
5.5 For multi-component kits, the labels and claims shall be consistent with the
documented evaluation of the components, in the package in contact with the
circulatory, lymphatic or cerebrospinal fluid system. This label should be consistent
with the intended clinical use of the package and its components.
5.6 Product endotoxin limits shall be determined, in accordance with appropriate
regulatory requirements.
Note: Endotoxin limits for medical infusion (blood) and injection equipment are recommended
in GB/T 14233.2-2005.
6 Selection of product unit
6.1 The sampling criteria for the selection of product units, in the bacterial endotoxin
test, are based on the premise that the production process is controlled and the
requirements of the quality management system are met.
6.2 The selection of test product units shall be based on the criteria, as specified in the
sampling plan, which may be based on regulatory requirements, published statistical
programs or guidelines, or validation of production runs.
6.3 The sampling parent (group) is generally defined as the production batch. If data
support different selection bases or alternatives for batch testing is selected, sample
selection can be based on the sampling parent being not a production batch. If
alternatives for batch testing is selected, see Chapter 10, B.6 ~ B.8, B.10.
Note: Sampling specifications, where the sampling matrix is not a production batch, should
include a risk assessment, to evaluate the suitability of the criteria for establishing the sampling
matrix (see Appendix B).
6.4 Test samples should be selected from the finished product, which includes all factors
that may affect or increase endotoxin levels (e.g., packaging).
Note: Samples for endotoxin testing may be selected from products, which are rejected in other
production quality items, provided that the rejected samples represent non-rejected products.
6.5 Samples may include pre-sterilized and post-sterilized products. The sterilized
sample contains all the factors that could affect the product or endotoxin testing. If
sample testing before sterilization is selected, the acceptability of the sample to
represent the endotoxin level of the final product shall be documented. The inspection
procedures performed should consistently reflect pre-sterilized or post-sterilized
samples. See B.6.5 for guidance on validation of equivalence.
Note: For products that promote microbial growth, it may not be appropriate to select samples
prior to sterilization.
6.6 In the inspection of multi-component kits (program packages) or complete sets of
products, depending on the use of the product, sometimes each component can be
evaluated individually, sometimes all the contents can be regarded as a whole for
evaluation. Standard test procedures should be applied to each component case. When
using a product kit or kit as a stand-alone unit, consideration shall be given to sample
preparation and applicable product endotoxin limits, without changing the method. See
B.6.6, for more guidance.
7 Choice of technique
7.1 Testing laboratories currently have three bacterial endotoxin testing techniques to
choose from. The selection of each technique should be based on adequate evaluation
of laboratory skills, experience, sample size requirements, data handling requirements,
test sample properties. Current techniques and methods include:
a) Gel-clot technique: Limit test and determination method;
b) Chromogenic techniques: Kinetic and endpoint methods;
c) Turbidity techniques: Kinetic and endpoint methods.
See Appendix B, for information on the three methods.
7.2 The selected method shall be confirmed, in accordance with Chapter 8. If the test
method or technique is changed, validation/verification shall be carried out (see 8.6).
8 Methodological validation
8.1 Identification of test endotoxin limits
8.1.1 The test endotoxin limit is defined as the maximum allowable concentration of
endotoxin, which may exist in the extract of a product, which is related to the product
endotoxin limit. See Appendix B, to determine product endotoxin limits.
8.1.2 Once the product endotoxin limit is determined, the test endotoxin limit can be
calculated, according to formula (1):
Medical device test endotoxin limit (EU/mL) = KN/V ………………………… (1)
Where:
a) BET testing laboratory changes;
b) Changes to BET materials, equipment that may affect the test; and
c) Changes to lambda of Limulus amebocyte lysate.
Note: Product positive controls (PPCs) are available for validation in some cases. PPC may
adequately detect that a change has occurred.
9 Use of technique
9.1 Key test parameters
9.1.1 Temperature
The general incubation temperature for bacterial endotoxin test methods is (37 ± 1) °C.
Refer to the reagent manufacturer's instructions for selection of appropriate parameters.
9.1.2 Time
Limulus amebocyte lysate manufacturer's product instructions give the reagent addition
and incubation time length. The general incubation time of gel bacterial endotoxin test
method is (60 ± 2) min.
9.1.3 pH
The manufacturer's instructions for the Limulus amebocyte lysate will give the
optimum pH range, for endotoxin response. A pH outside this range in the test may
cause interference. If the pH of the product positive control is acceptable, in the
validation test, subsequent pH measurements may not be required. However, if the pH
must be adjusted in validation, the pH shall be measured, in subsequent routine tests.
9.2 Equipment and reagents
9.2.1 Since the bacterial endotoxin test requires a limited temperature range, the heating
box or water bath, which is used for the incubation of the gel-clot test, shall record the
temperature during the incubation. Mechanical pipettes (including fixed, adjustable,
reusable units) shall be calibrated regularly. If the laboratory uses chromogenic or
turbidity techniques, the hardware and software shall be identified, in accordance with
the manufacturer's instructions for use and validation requirements. Materials that are
not non-pyrogenic supplies (e.g., microplates), shall be carefully evaluated before use
(see 4.6.4), to ensure that they do not interfere with the determination in the testing
laboratory.
9.2.2 All limulus amebocyte lysates used in the test shall be certified products. The
activity of the control standard endotoxin shall be calibrated, by the national endotoxin
standard, which shall be carried out by the testing laboratory OR the Limulus
amebocyte lysate manufacturer provides the calibration documents to the testing
laboratory.
9.2.3 The product label of the Limulus amebocyte lysate manufacturer will give storage
requirements for lyophilized and reconstituted reagents. If the storage conditions in the
laboratory are different from those recommended by the manufacturer, the storage
conditions shall be confirmed.
9.3 Sample preparation
9.3.1 General
9.3.1.1 Samples for testing should be collected and stored, in a manner that prevents
changes in endotoxin levels.
9.3.1.2 The routine bacterial endotoxin test shall adopt the sample
preparation/extraction method, which is used for validation. The product can be rinsed
or soaked, to prepare a test rinse or leaching solution. The leaching method used
depends on the product labelled as non-pyrogenic.
Note: For a long time, there has been no recognized extraction method for bacterial endotoxin
test. However, endotoxin limits have been established with a safety factor, to ensure patient
safety (see Appendix A.8).
9.3.2 Medical devices
9.3.2.1 The instruments are usually leached together, for routine endotoxin testing.
When the test determines the endotoxin level per device or the variability between
devices, the device needs to be tested separately. See Appendix B or relevant regulations,
for guidelines on the appropriate sample size.
9.3.2.2 In order to ensure the safety of the patient's pyrogenic threshold, usually the
endotoxin limit of a batch refers to the measured value of a maximum of 10 devices,
which are pooled together. If a device unit is tested, the endotoxin limit of the product
can be evaluated. Additional information is given in B.8.1.1.
9.3.2.3 The instruments are usually immersed in LRW for sample extraction.
Depyrogenation equipment can be used to separate or disassemble the instruments for
extraction. The shortest extraction time is 15 min at 37 °C ~ 40 °C, OR not less than 1
h at controlled room temperature (generally 18 °C ~ 25 °C), OR other proven equivalent
conditions. It is recommended to supplement the leaching process with agitation.
9.3.2.4 For the instruments marked with "non-pyrogenic liquid circuit", inject the
endotoxin test water, which has been heated to 37 °C ± 1 °C, into the liquid circuit, so
that the extract is in contact with the liquid circuit, at a controlled room temperature
(usually 18 °C ~ 25 °C) for not less than 1 h, OR other equivalent conditions. When
appropriate, the extracts of each sample are mixed, to obtain a pooled sample test
product positive control is 50% ~ 200% of the known concentration of added
endotoxin.
9.5.2 For the gel limit test, it is acceptable, if the validity of each parameter of the test
product complies with 9.5.1 AND both test tubes of the sample solution are negative.
If a positive result appears in any sample tube, see Appendix C.
9.5.3 For gel-clot determination, determine the endotoxin concentration in the sample
solution, by calculating the end point concentration of each series of parallel tubes AND
multiplying the dilution factor of each end point by λ. The endotoxin concentration of
the sample is the geometric mean end point concentration of each parallel tube dilution
series. When necessary, the endotoxin concentration of the sample solution can be used
to calculate the total endotoxin per unit of product, using appropriate mathematical
factors (i.e., sample/extract volume, product weight, sample to product ratio, etc.).
If the diluted sample solution is used in the test, the endotoxin concentration is
calculated, by multiplying the leaching stock solution by the dilution factor.
It is acceptable, if the measured endotoxin level of the test sample is less than the
product's endotoxin limit.
If the endotoxin of the test sample is greater than the product limit, see Appendix C.
9.5.4 In the chromogenic method and the turbidimetric method, if the average endotoxin
concentration of each tube of the sample solution is less than the product endotoxin
limit, after the dilution, AND concentration is corrected, the test preparation meets the
test.
9.5.5 If the endotoxin level exceeds the product endotoxin limit, see Appendix C.
9.6 Change control
See 8.6, for specific requirements for maintaining product identification/validation.
9.7 Out-of-specification values and failure investigation
When a sample exceeds the endotoxin limit of the product, it shall be investigated (see
Appendix C).
10 Alternatives to batch testing
Note: See Appendix B for specific guidance on alternatives to batch testing.
10.1 General
Product release batch inspection of the final product is usually used, to determine that